Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) and PTC Therapeutics (NASDAQ:PTCT – Get Free Report) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.
Institutional and Insider Ownership
80.4% of Spyre Therapeutics shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by company insiders. Comparatively, 5.3% of PTC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of recent ratings and target prices for Spyre Therapeutics and PTC Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Spyre Therapeutics | 1 | 1 | 13 | 2 | 2.94 |
| PTC Therapeutics | 2 | 3 | 10 | 1 | 2.62 |
Spyre Therapeutics currently has a consensus price target of $110.40, suggesting a potential upside of 38.17%. PTC Therapeutics has a consensus price target of $95.07, suggesting a potential upside of 60.49%. Given PTC Therapeutics’ higher possible upside, analysts clearly believe PTC Therapeutics is more favorable than Spyre Therapeutics.
Earnings and Valuation
This table compares Spyre Therapeutics and PTC Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Spyre Therapeutics | $890,000.00 | 9,149.00 | -$155.20 million | ($1.95) | -40.97 |
| PTC Therapeutics | $1.73 billion | 2.86 | $682.64 million | ($0.58) | -102.14 |
PTC Therapeutics has higher revenue and earnings than Spyre Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Spyre Therapeutics has a beta of 3.1, suggesting that its stock price is 210% more volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500.
Profitability
This table compares Spyre Therapeutics and PTC Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Spyre Therapeutics | N/A | -30.74% | -22.23% |
| PTC Therapeutics | -3.80% | N/A | -1.32% |
Summary
Spyre Therapeutics beats PTC Therapeutics on 9 of the 15 factors compared between the two stocks.
About Spyre Therapeutics
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
About PTC Therapeutics
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
